摘要
目的评价全髋关节置换术(THA)后患者用利伐沙班和低分子肝素抗凝的疗效和安全性。方法 145例初次行THA的患者,随机分成2组,利伐沙班组75例,术后每日口服利伐沙班10 mg至术后10 d;低分子肝素组70例,术后每日皮下注射低分子肝素0.4 mg,至术后10 d。观察术后患者伤口出血情况;术后48 h内拔除引流管,计算术后引流量;术后7 d观察凝血指标变化值;术后7～10d超声检查深静脉血栓形成情况。结果术后深静脉血栓(DVT)形成情况,出血倾向和术后引流量,2组患者差异无统计学意义。术后7 d凝血指标与术前比较,利伐沙班组的凝血酶原时间(PT)较术前延长,低分子肝素组差异无统计学意义。术后7 d国际标准化比值(INR)与术前比较,2组变化无统计学意义。结论利伐沙班与低分子肝素相比,预防THA术后的疗效相当,在安全性方面,均无大出血事件的发生。
Objective To evaluate the effectiveness and safety of oral ri varoxaban （Xareho） with nadroparin （ Fraxiparine ） for preventing venous thromboembolism （ VTE ） after total hip arthroplasty. Methods One hundred and forty five patients matched with the inclusion criteria with primary total hip arthroplsty were randomly divided into 2 groups. Rivar oxaban group （75 cases） took oral rivaroxaban 10 mg once daily for 10 days after operation, while LMWH （low molecular weight heparin） group （70 cases） took subcutaneous injection of 0. 4 mg once daily for l0 days after operation. Deep venous thrombosis （DVT） were examined by the color doppler ultrasonic in 7 10 days after operation. Bleeding was ob served after operation. Drainage volume were calculated within 48 hours after removal of the drainage tube. The variation values of coagulation pa rameters were observed at 7th day after operation. Results Deep venous thrombosis, bleeding tendency and drainage volume showed no statistical ly significant difference between the two groups after operations. Pro thrombin time（PT） of rivaroxaban group was prolonged at 7th day after operation comparing with preoperation. International normalized ratio （INR） of both groups showed no significant change at 7th day after oper ation comparing with preoperation. Conclusion Comparing with LMWH, rivaroxaban had the same effectiveness to prevent DVT after total hip joint arthroplasty. There had no major bleeding events in two groups.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2013年第4期260-262,共3页
The Chinese Journal of Clinical Pharmacology
